Phase 1 Study of Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

This study is testing a new combination of two drugs, Niraparib and Osimertinib, to see if they can help treat people with advanced lung cancer. The goal is to see if adding Niraparib to the standard treatment helps stop cancer cells from repairing themselves, which could provide a new option when current treatments stop working.

This trial is for people with stage 4 non-small cell lung cancer that has a specific genetic change called an EGFR mutation. You must have already been treated with Osimertinib and seen your cancer grow, and you should not have taken a type of drug called a PARP inhibitor before.

Participants will take a combination of these two medications as part of their cancer care. Because this is a Phase 1 study, the main goal is to find the right dosage while closely monitoring your health and how your body reacts to the treatment.

The study is currently taking place at several locations in Boston, Massachusetts. Its status is listed as unknown, so it is important to contact the researchers directly to see if they are currently enrolling new patients.